Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
Vedolizumab for induction and maintenance of remission in Crohn's disease
Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation
Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN
Vedolizumab safety in pregnancy and newborn outcomes
Vedolizumab in Patients With Common Variable Immune Deficiency and Gut Inflammation
Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study
Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers
Vedolizumab for induction and maintenance of remission in ulcerative colitis
Vedolizumab: An a alpha(4)beta(7) Integrin Inhibitor for Inflammatory Bowel Diseases
Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?
Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis
Vedolizumab Is Safe and Effective in Elderly Patients with Inflammatory Bowel Disease
Vedolizumab: A Review of Its Use in Adult Patients with Moderately to Severely Active Ulcerative Colitis or Crohn%26apos;s Disease
Vedolizumab: First Global Approval
Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis
Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis (vol 35, pg 412, 2015)
Vedolizumab, a monoclonal antibody to the gut homing 01.4137 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype
Vedolizumab Concentrations in the Breast Milk of Nursing Mothers With Inflammatory Bowel Disease
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease
Vedolizumab-Associated Pancreatitis in Paediatric Ulcerative Colitis: Functional Selectivity of the alpha 4 beta 7integrin and MAdCAM-1 Pathway?
Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis
Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety
Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis
Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN (vol 11, pg 1230, 2017)
Vedral, V.: Decoding Reality: the Universe as Quantum Information